Nordea Investment Management
NBIX icon

Nordea Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Nordea Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.2M Buy
319,058
+275,922
+640% +$40.9M 0.04% 272
2026
Q1 		$5.68M Buy
43,136
+15,934
+59% +$2.11M 0.01% 550
2025
Q4 		$3.83M Buy
27,202
+12,195
+81% +$1.77M ﹤0.01% 645
2025
Q3 		$2.07M Buy
15,007
+6,183
+70% +$838K ﹤0.01% 734
2025
Q2 		$1.11M Buy
8,824
+1,196
+16% +$137K ﹤0.01% 807
2025
Q1 		$850K Buy
7,628
+30
+0.4% +$3.8K ﹤0.01% 827
2024
Q4 		$1.04M Hold
7,598
– – ﹤0.01% 800
2024
Q3 		$875K Sell
7,598
-20,344
-73% -$2.79M ﹤0.01% 822
2024
Q2 		$3.84M Buy
27,942
+1,259
+5% +$173K ﹤0.01% 581
2024
Q1 		$3.68M Sell
26,683
-65
-0.2% -$8.88K ﹤0.01% 601
2023
Q4 		$3.54M Sell
26,748
-1,843
-6% -$212K ﹤0.01% 607
2023
Q3 		$3.28M Buy
28,591
+19,238
+206% +$2.03M ﹤0.01% 607
2023
Q2 		$890K Sell
9,353
-419
-4% -$40.9K ﹤0.01% 834
2023
Q1 		$966K Sell
9,772
-3,174
-25% -$330K ﹤0.01% 795
2022
Q4 		$1.54M Sell
12,946
-7,115
-35% -$833K ﹤0.01% 703
2022
Q3 		$2.1M Sell
20,061
-357,598
-95% -$36.3M ﹤0.01% 675
2022
Q2 		$36.5M Sell
377,659
-142,851
-27% -$13.2M 0.05% 242
2022
Q1 		$48.6M Sell
520,510
-38,694
-7% -$3.28M 0.06% 243
2021
Q4 		$47.6M Buy
559,204
+96,375
+21% +$8.87M 0.06% 252
2021
Q3 		$44.1M Buy
462,829
+80,143
+21% +$7.57M 0.06% 263
2021
Q2 		$37.2M Buy
382,686
+191,140
+100% +$18.3M 0.05% 277
2021
Q1 		$18.6M Buy
191,546
+33,344
+21% +$3.5M 0.03% 318
2020
Q4 		$15.2M Buy
158,202
+48,738
+45% +$4.71M 0.02% 325
2020
Q3 		$10.8M Sell
109,464
-86,846
-44% -$10M 0.02% 325
2020
Q2 		$24.6M Buy
196,310
+110,724
+129% +$12.2M 0.03% 304
2020
Q1 		$7.76M Buy
85,586
+9,452
+12% +$925K 0.02% 348
2019
Q4 		$8.16M Sell
76,134
-61,347
-45% -$6.42M 0.02% 358
2019
Q3 		$12.3M Buy
137,481
+83,777
+156% +$7.83M 0.03% 319
2019
Q2 		$4.54M Buy
53,704
+14,708
+38% +$1.21M 0.01% 531
2019
Q1 		$3.44M Buy
38,996
+465
+1% +$38.9K 0.01% 756
2018
Q4 		$2.75M Hold
38,531
– – 0.01% 775
2018
Q3 		$4.74M Buy
38,531
+5,939
+18% +$674K 0.01% 591
2018
Q2 		$3.2M Sell
32,592
-4,243
-12% -$380K 0.01% 599
2018
Q1 		$3.06M Buy
36,835
+3,284
+10% +$277K 0.01% 596
2017
Q4 		$2.6M Sell
33,551
-6,096
-15% -$416K 0.01% 560
2017
Q3 		$2.43M Sell
39,647
-1,585
-4% -$83.6K 0.01% 560
2017
Q2 		$1.9M Buy
+41,232
New +$2M ﹤0.01% 645

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Nordea Investment Management's NBIX Position: Q2 2026 in Review

Nordea Investment Management increased its Neurocrine Biosciences (NBIX) stake by 640% in Q2 2026, buying an estimated $40.9M and bringing the position to 319,058 shares worth $54.2M. The position accounts for 0.04% of the portfolio, ranked #272.

Nordea Investment Management first reported a position in NBIX in Q2 2017 and has held it in 37 quarters since. 318 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Nordea Investment Management held 319,058 shares of Neurocrine Biosciences worth $54.2M as of Q2 2026.
  • Nordea Investment Management bought 275,922 Neurocrine Biosciences shares in Q2 2026, an estimated $40.9M.
  • Neurocrine Biosciences made up 0.04% of Nordea Investment Management's portfolio in Q2 2026, its #272 holding.
  • Nordea Investment Management first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 37 quarters since.
  • 318 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.